33
Views
5
CrossRef citations to date
0
Altmetric
Commentary

Antiangiogenesis: A new approach to the treatment of lymphoma

Pages 454-455 | Published online: 01 Jul 2009

References

  • Jørgensen J M, Sarensen F B, Bendix K, Nielsen J L, Olsen M L, Funder A MD, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48(3)584–595
  • Arias V, Soares F A. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphoma and florid follicular hyperplasia: a morphometric study. Leuk Lymphoma 2000; 40: 157–166
  • Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukine-6 as independent predictors of prognosis in non-Hodgkin's lymphoma. Eur J Haemotol 2002; 68: 91–100
  • Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood 2000; 96: 3712–3718
  • Levine A M, Tulpule A, Quinn D I, Gorospe G 3rd, Smith D L, Hornor L, et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24: 1712–1719
  • Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weienbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005
  • Stopeck A, Iannone M, Rimsza L, Miller T, Fisher R, Bellamy W, et al. Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: correlative studies from the SWOG S0108 trial. Blood 2004; 104: 629a, (Abstract 2288)
  • Stopeck A, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher R I, et al. Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol 2005; 23(Suppl)583s, (Abstract 6592)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.